The challenges of implementing pharmacogenomic testing in the clinic

References

• Johnson JA. Pharmacogenetics in clinical practice: how far have we come and where are we going? Pharmacogenomics. 2013;14(7):835–843.
   PubMed Web of Science ®Google Scholar
• Garrod AE. The inborn factors of disease. London, UK: Oxford University Press; 1931.
   Google Scholar
• Meyer UA. Pharmacogenetics - five decades of therapeutic lessons from genetic diversity. Nat Rev Genet. 2004;5(9):669–676.
   PubMed Web of Science ®Google Scholar
• Distlerath LM, Reilly PE, Martin MV, et al. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem. 1985;260(15):9057–9067.
   PubMed Web of Science ®Google Scholar
• Skoda RC, Gonzalez FJ, Demierre A, et al. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci U S A. 1988;85(14):5240–5243.
   PubMed Web of Science ®Google Scholar
• De Morais SM, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994;46(4):594–598.
   PubMed Web of Science ®Google Scholar
• Blum M, Demierre A, Grant DM, et al. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci U S A. 1991;88(12):5237–5241.
   PubMed Web of Science ®Google Scholar
• Ji Y, Skierka JM, Blommel JH, et al. Preemptive pharmacogenomic testing for precision medicine: a comprehensive analysis of five actionable pharmacogenomic genes using next-generation DNA sequencing and a customized CYP2D6 genotyping cascade. J Mol Diagn. 2016;18(3):438–445.
   PubMed Web of Science ®Google Scholar
• Van Driest SL, Shi Y, Bowton EA, et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clin Pharmacol Ther. 2014;95(4):423–431.
   PubMed Web of Science ®Google Scholar
• Bush WS, Crosslin DR, Owusu-Obeng A, et al. Genetic variation among 82 pharmacogenes: the PGRNseq data from the eMERGE network. Clin Pharmacol Ther. 2016;100(2):160–169.
   PubMed Web of Science ®Google Scholar
• St Sauver JL, Bielinski SJ, Olson JE, et al. Integrating pharmacogenomics into clinical practice: promise vs reality. Am J Med. 2016;129(10):1093–9.e1.
   PubMed Web of Science ®Google Scholar
• Stanek EJ, Sanders CL, Taber KAJ, et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther. 2012;91(3):450–458.
   PubMed Web of Science ®Google Scholar
• Haga SB, Burke W, Ginsburg GS, et al. Primary care physicians’ knowledge of and experience with pharmacogenetic testing. Clinical Genetics. 2012;82(4):388–394.
   PubMed Web of Science ®Google Scholar
• Scott SA. Personalizing medicine with clinical pharmacogenetics. Genet Med. 2011;13(12):987–995.
   PubMed Web of Science ®Google Scholar
• Suarez-Kurtz G, Botton MR. Pharmacogenomics of warfarin in populations of African descent. Br J Clin Pharmacol. 2013;75(2):334–346.
   PubMed Web of Science ®Google Scholar
• Hovelson DH, Xue Z, Zawistowski M, et al. Characterization of ADME gene variation in 21 populations by exome sequencing. Pharmacogenet Genomics. 2017;27(3):89–100.
   PubMed Web of Science ®Google Scholar
• Kozyra M, Ingelman-Sundberg M, Lauschke VM. Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. Genet Med. 2017;19(1):20–29.
   PubMed Web of Science ®Google Scholar
• Wetterstrand KA Data from the NHGRI Genome Sequencing Program (GSP). [cited 2017 Aug 04]. Available from: www.genome.gov/sequencingcostsdata.
   Google Scholar
• Van El CG, Cornel MC, Borry P, et al. Whole-genome sequencing in health care. Recommendations of the European Society of Human Genetics. Eur J Hum Genet. 2013;21(Suppl 1):S1–5.
   PubMed Web of Science ®Google Scholar
• Mizzi C, Peters B, Mitropoulou C, et al. Personalized pharmacogenomics profiling using whole-genome sequencing. Pharmacogenomics. 2014;15(9):1223–1234.
   PubMed Web of Science ®Google Scholar
• Ng D, Hong CS, Singh LN, et al. Assessing the capability of massively parallel sequencing for opportunistic pharmacogenetic screening. Genet Med. 2017;19(3):357–361.
   PubMed Web of Science ®Google Scholar
• Kalman LV, Agundez J, Appell ML, et al. Pharmacogenetic allele nomenclature: international workgroup recommendations for test result reporting. Clin Pharmacol Ther. 2016;99(2):172–185.
   PubMed Web of Science ®Google Scholar
• Moyer AM, Vitek CRR, Giri J, et al. Challenges in ordering and interpreting pharmacogenomic tests in clinical practice. Am J Med. 2017. doi:10.1016/j.amjmed.2017.07.012. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Fricke-Galindo I, Cespedes-Garro C, Rodrigues-Soares F, et al. Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes across world populations. Pharmacogenomics J. 2016;16(2):113–123.
   PubMed Web of Science ®Google Scholar
• Caudle KE, Dunnenberger HM, Freimuth RR, et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2017;19(2):215–223.
   PubMed Web of Science ®Google Scholar
• Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–424.
   PubMed Web of Science ®Google Scholar
• Clinical Pharmacogenetics Implementation Consortium (CPIC). [cited 2017 Sep 16].  Available from: www.cpicpgx.org.
   Google Scholar
• The Pharmacogenomics Knowledge Base (PharmGKB). [cited 2017 Sep 16]. Available from: www.pharmgkb.org.
   Google Scholar
• The human cytochrome P450 (CYP) allele nomenclature database. [cited 2017 Sep 16]. Available from: www.cypalleles.ki.se.
   Google Scholar
• Pharmacogene variation consortium (PharmVar). [cited 2017 Sep 16]. Available from: http://www.pgrn.org/pharmvar.html.
   Google Scholar
• Hicks JK, Swen JJ, Gaedigk A. Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization. Curr Drug Metab. 2014;15(2):218–232.
   PubMed Web of Science ®Google Scholar
• Relling M, Cpic: KT. clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther. 2011;89(3):464–467.
   PubMed Web of Science ®Google Scholar
• Thorn CF, Klein TE, Altman RB. PharmGKB: the pharmacogenetics and pharmacogenomics knowledge base. Methods Mol Biol. 2005;311:179–191.
   PubMedGoogle Scholar
• Wu AH. Genotype and phenotype concordance for pharmacogenetic tests through proficiency survey testing. Arch Pathol Lab Med. 2013;137(9):1232–1236.
   PubMed Web of Science ®Google Scholar
• Liu Y, Jeong H, Takahashi H, et al. Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism. Clin Pharmacol Ther. 2012;91(4):660–665.
   PubMed Web of Science ®Google Scholar
• Bielinski SJ, Olson JE, Pathak J, et al. Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. Mayo Clinic Proceedings. 2014;89(1):25–33.
   PubMed Web of Science ®Google Scholar
• Weitzel KW, Alexander M, Bernhardt BA, et al. The IGNITE network: a model for genomic medicine implementation and research. BMC Med Genomics [Electronic Resource]. 2016;9:1.
   PubMed Web of Science ®Google Scholar
• Van Der Wouden CH, Cambon-Thomsen A, Cecchin E, et al. Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium. Clin Pharmacol Ther. 2016;101(3):341–358.
   Web of Science ®Google Scholar
• Rasmussen-Torvik LJ, Stallings SC, Gordon AS, et al. Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems. Clin Pharmacol Ther. 2014;96(4):482–489.
   PubMed Web of Science ®Google Scholar
• Pulley JM, Denny JC, Peterson JF, et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther. 2012;92(1):87–95.
   PubMed Web of Science ®Google Scholar
• Nishimura AA, Shirts BH, Dorschner MO, et al. Development of clinical decision support alerts for pharmacogenomic incidental findings from exome sequencing. Genet Med. 2015;17(11):939–942.
   PubMed Web of Science ®Google Scholar
• Hoffman JM, Haidar CE, Wilkinson MR, et al. PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. Am J Med Genet C, Semin Med Genet. 2014;166C(1):45–55.
   PubMed Web of Science ®Google Scholar
• Caraballo PJ, Hodge LS, Bielinski SJ, et al. Multidisciplinary model to implement pharmacogenomics at the point of care. Genet Med. 2016;22:22.
   Google Scholar
• Roberts JD, Wells GA, Le May MR, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet. 2012;379(9827):1705–1711.
   PubMed Web of Science ®Google Scholar
• Vu CL, Chan J, Todaro M, et al. Point-of-care molecular diagnostic devices: an overview. Pharmacogenomics. 2015;16(12):1399–1409.
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Newman WG, Elliott RA, et al. The cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprine. Value Health. 2014;17(1):22–33.
   PubMed Web of Science ®Google Scholar
• Guzauskas GF, Hughes DA, Bradley SM, et al. A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention. Clin Pharmacol Ther. 2012;91(5):829–837.
   PubMed Web of Science ®Google Scholar
• Pink J, Pirmohamed M, Lane S, et al. Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs Alternative Anticoagulation in Atrial Fibrillation. Clin Pharmacol Ther. 2014;95(2):199–207.
   PubMed Web of Science ®Google Scholar
• Dong D, Sung C, Finkelstein EA. Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. Neurology. 2012;79(12):1259–1267.
   PubMed Web of Science ®Google Scholar
• Rattanavipapong W, Koopitakkajorn T, Praditsitthikorn N, et al. Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand. Epilepsia. 2013;54(9):1628–1638.
   PubMed Web of Science ®Google Scholar
• Kapoor R, Martinez-Vega R, Dong D, et al. Reducing hypersensitivity reactions with HLA-B*5701 genotyping before abacavir prescription: clinically useful but is it cost-effective in Singapore? Pharmacogenet Genomics. 2015;25(2):60–72.
   PubMed Web of Science ®Google Scholar
• Senatore C, Charlier B, Truono A, et al. A prospective screening of HLA-B*57.01 allelic variant for preventing the hypersensivity reaction to abacavir: experience from the laboratory of molecular biology of the infectious diseases division at the University Hospital of Salerno. Transl Med UniSa. 2015;11:55–58.
   PubMed Web of Science ®Google Scholar
• Berm EJ, Looff M, Wilffert B, et al. Economic evaluations of pharmacogenetic and pharmacogenomic screening tests: a systematic review. Second Update of the Literature. PLoS One. 2016;11(1):e0146262.
   PubMed Web of Science ®Google Scholar
• Verbelen M, Weale ME, Lewis CM. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? Pharmacogenomics J. 2017.
   PubMed Web of Science ®Google Scholar
• Plumpton CO, Roberts D, Pirmohamed M, et al. A systematic review of economic evaluations of pharmacogenetic testing for prevention of adverse drug reactions. Pharmacoeconomics. 2016;34(8):771–793.
   PubMed Web of Science ®Google Scholar
• Grosse SD. Economic analyses of genetic tests in personalized medicine: clinical utility first, then cost utility. Genet Med. 2014;16(3):225–227.
   PubMed Web of Science ®Google Scholar
• O’Donnell P, Bush A, Spitz J, et al. The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin Pharmacol Ther. 2012;92(4):446–449.
   PubMed Web of Science ®Google Scholar
• Carpenter JS, Rosenman MB, Knisely MR, et al. Pharmacogenomically actionable medications in a safety net health care system. SAGE Open Med. 2016;4:2050312115624333.
   Google Scholar
• Dunnenberger HM, Crews KR, Hoffman JM, et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol. 2015;55:89–106.
   PubMed Web of Science ®Google Scholar
• Deverka PA. Pharmacogenomics, evidence, and the role of payers. Public Health Genomics. 2009;12(3):149–157.
   PubMed Web of Science ®Google Scholar
• Organization WH. Human genomics in global health: genomics and policy 2017. [cited 2017 Sep 16]. Available from: www.who.int/genomics/policy/Genomicsandpolicy/en/.
   Google Scholar
• Vozikis A, Cooper DN, Mitropoulou C, et al. Test pricing and reimbursement in genomic medicine: towards a general strategy. Public Health Genomics. 2016;19(6):352–363.
   PubMed Web of Science ®Google Scholar
• Veenstra D, Burke W. Pharmacogenomics and public health. Public Health Genomics. 2009;12(3):131–133.
   PubMed Web of Science ®Google Scholar
• Hresko A, Haga SB. Insurance coverage policies for personalized medicine. J Pers Med. 2012;2(4):201–216.
   PubMedGoogle Scholar
• Schildcrout JS, Shi Y, Danciu I, et al. A prognostic model based on readily available clinical data enriched a pre-emptive pharmacogenetic testing program. J Clin Epidemiol. 2016;72:107–115.
   PubMed Web of Science ®Google Scholar
• Caudle KE, Klein TE, Hoffman JM, et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab. 2014;15(2):209–217.
   PubMed Web of Science ®Google Scholar
• Swen JJ, Nijenhuis M, De Boer A, et al. Pharmacogenetics: from bench to byte— an update of guidelines. Clin Pharmacol Ther. 2011;89(5):662–673.
   PubMed Web of Science ®Google Scholar
• Adults DPoAGf. Research aAAWGotOoA, (OARAC) AC. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2011. [cited 2017 Aug 5]. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
   Google Scholar
• American College of Emergency P, Society for Cardiovascular A, Interventions. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61(4):e78–140.
   PubMed Web of Science ®Google Scholar
• Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e152S–e84S.
   PubMed Web of Science ®Google Scholar
• U. S. Food and Drug Administration. Table of pharmacogenomic biomarkers in drug labeling 2017 [ updated May 20/2015. [cited 2017 Aug 4]. Available from: http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm.
   Google Scholar
• O’Connor SK, Michaels N, Ferreri S. Expansion of pharmacogenomics into the community pharmacy: billing considerations. Pharmacogenomics. 2015;16(3):175–180.
   PubMed Web of Science ®Google Scholar
• Vo TT, Bell GC, Owusu Obeng A, et al. Pharmacogenomics implementation: considerations for selecting a reference laboratory. Pharmacotherapy. 2017 Sep;37(9):1014-1022.
   Google Scholar
• GTR: genetic testing registry. [cited 2017 Sep 16]. Available from: www.ncbi.nlm.nih.gov/gtr/.
   Google Scholar
• GeneTests. [cited 2017 Sep 16]. Available from: www.genetests.org/.
   Google Scholar
• Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343–350.
   PubMed Web of Science ®Google Scholar
• Gibson ML, Hohmeier KC, Smith CT. Pharmacogenomics testing in a community pharmacy: patient perceptions and willingness-to-pay. Pharmacogenomics. 2017;18(3):227–233.
   PubMed Web of Science ®Google Scholar
• Bielinski SJ, St Sauver JL, Olson JE, et al. Are patients willing to incur out-of-pocket costs for pharmacogenomic testing? Pharmacogenomics J. 2017;17(1):1–3.
   PubMed Web of Science ®Google Scholar
• Olson JE, Rohrer Vitek CR, Bell EJ, et al. Participant-perceived understanding and perspectives on pharmacogenomics: the Mayo Clinic RIGHT protocol (Right Drug, Right Dose, Right Time). Genet Med. 2017;19(7):819–825.
   PubMed Web of Science ®Google Scholar
• Moaddeb J, Haga SB. Pharmacogenetic testing: current evidence of clinical utility. Ther Adv Drug Saf. 2013;4(4):155–169.
   PubMedGoogle Scholar
• Schwartz JB, Kane L, Moore K, et al. Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin. J Am Med Dir Assoc. 2011;12(9):633–638.
   PubMed Web of Science ®Google Scholar
• Kimmel SE, French B, Kasner SE, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013;369:2283–2293.
   PubMed Web of Science ®Google Scholar
• Peterson JF, Field JR, Shi Y, et al. Attitudes of clinicians following large-scale pharmacogenomics implementation. Pharmacogenomics J. 2016;16(4):393–398.
   PubMed Web of Science ®Google Scholar
• Owusu-Obeng A, Weitzel KW, Hatton RC, et al. Emerging roles for pharmacists in clinical implementation of pharmacogenomics. Pharmacotherapy:The J Hum Pharmacol Drug Ther. 2014;34(10):1102–1112.
   Google Scholar
• Formea CM, Nicholson WT, Vitek CR. An inter-professional approach to personalized medicine education: one institution’s experience. Per Med. 2015;12(2):129–138.
   PubMed Web of Science ®Google Scholar
• Ferreri SP, Greco AJ, Michaels NM, et al. Implementation of a pharmacogenomics service in a community pharmacy. J Am Pharm Assoc (2003). 2014;54(2):172–180.
   PubMed Web of Science ®Google Scholar
• ASHP statement on the pharmacist’s role in clinical pharmacogenomics. American Society of Health-System Pharmacists Section of Clinical Specialists and Scientists Section Advisory Group on Emerging Sciences. Am J Health-System Pharm. 2015;72(7):579–581.
   PubMedGoogle Scholar
• Lee KC, Hudmon KS, Ma JD, et al. Evaluation of a shared pharmacogenomics curriculum for pharmacy students. Pharmacogenomics. 2015;16(4):315–322.
   PubMed Web of Science ®Google Scholar
• McCullough KB, Formea CM, Berg KD, et al. Assessment of the pharmacogenomics educational needs of pharmacists. Am J Pharm Educ. 2011;75(3):51.
   PubMed Web of Science ®Google Scholar
• Haga SB, Moaddeb J. Proposal for a pharmacogenetics certificate program for pharmacists. Pharmacogenomics. 2016;17(6):535–539.
   PubMed Web of Science ®Google Scholar
• American Society of Health-Systems Pharmacists (ASHP). [cited 2017 Sep 17]. Available from: https://www.ashp.org.
   Google Scholar
• RxGenomix Pharmacogenomics Course. [cited 2017 Sep 17]. Available from: http://www.rxgenomix.com/courses/pharma.
   Google Scholar
• PharmGenEd. [cited 2017 Sep 17]. Available from: http://pharmacogenomics.ucsd.edu.
   Google Scholar
• Genetics/Genomics Compentency Center (G2C2). [cited 2017 Sep 17]. Available from: http://genomicseducation.net.
   Google Scholar
• Bell GC, Crews KR, Wilkinson MR, et al. Development and use of active clinical decision support for preemptive pharmacogenomics. J Am Med Inform Assoc. 2014;21(e1):e93–9.
   PubMed Web of Science ®Google Scholar
• Hicks JK, Stowe D, Willner MA, et al. Implementation of clinical pharmacogenomics within a large health system: from electronic health record decision support to consultation services. Pharmacotherapy:J Hum Pharmacol Drug Ther. 2016;36(8):940–948.
   Google Scholar
• Mould DR, D’Haens G, Upton RN. Clinical decision support tools: the evolution of a revolution. Clin Pharmacol Ther. 2016;99(4):405–418.
   PubMed Web of Science ®Google Scholar
• Caraballo PJ, Bielinski SJ, St Sauver JL, et al. Electronic medical record-integrated pharmacogenomics and related clinical decision support concepts. Clin Pharmacol Ther. 2017;102(2):254–264.
   PubMed Web of Science ®Google Scholar
• Shirts BH, Salama JS, Aronson SJ, et al. CSER and eMERGE: current and potential state of the display of genetic information in the electronic health record. J Am Med Inform Association: JAMIA. 2015;22(6):1231–1242.
   PubMed Web of Science ®Google Scholar
• Samwald M, Minarro-Gimenez JA, Blagec K, et al. Towards a global IT system for personalized medicine: the medicine safety code initiative. Stud Health Technol Inform. 2014;198:25–31.
   PubMedGoogle Scholar
• Sukasem C, Chantratita W. A success story in pharmacogenomics: genetic ID card for SJS/TEN. Pharmacogenomics. 2016;17(5):455–458.
   PubMed Web of Science ®Google Scholar